FDA启动罕见病框架计划，评估罕见病药物与生物制品审评框架并自10月28日起公开征询意见

FDA’s rare disease framework effort will revisit evidence expectations and manufacturing review, with public input starting Oct. 28.

FDA has launched the Rare Disease Framework Initiative, a review of how the agency evaluates drugs and biologics for rare diseases, and will open public comment with an Oct. 28 meeting at its White Oak campus.¹ Announced Oct. 14, the effort is aimed at making regulatory advice and review more consistent for sponsors that must build evidence packages around very small patient populations.

For developers and manufacturers, the significance is procedural rather than immediate: no guidance or regulatory changes have been proposed, but the outcome could reshape expectations for evidence, review and inspections.

“A bold vision to reimagine the framework for rare disease drug development that builds on key learnings and milestones is necessary to meet this moment,” said Amy Comstock Rick, J.D., director of the Rare Disease Innovation Hub, which is leading the effort. “This new framework will enhance consistency and predictability for both sponsors and for patients.”¹

“Patients with rare diseases and their families deserve a regulatory process that addresses the uniqueness of each of their conditions while maintaining the FDA’s rigorous standards. A bold vision to reimagine the framework for rare disease drug development that builds on key learnings and milestones is necessary to meet this moment. This new framework will enhance consistency and predictability for both sponsors and for patients.”

What is the FDA Rare Disease Framework Initiative designed to change?

The initiative, outlined in an FDA white paper, will examine existing policies, programs, guidance and regulations for rare disease drug development, with emphasis on coordinating reviewer expertise, bringing patient perspectives in earlier and relying more on external disease experts.² Its scope runs from engagement before an investigational new drug application through post-approval obligations and chemistry, manufacturing and controls requirements.²

The hub leads the work with the Office of the Commissioner, the Center for Biologics Evaluation and Research and the Center for Drug Evaluation and Research.¹

After the Oct. 28 meeting, FDA plans sector-specific roundtables, requests for information and internal feedback sessions.^1,2 Possible outputs include new or revised guidance, regulatory revisions, staff training and organizational changes, though the agency presents these as possibilities, not commitments.^1,2

FDA says the framework will continue to meet the statutory safety and effectiveness standard.²

How could the framework affect manufacturing and quality review?

The initiative is a commitment to risk-based approaches in chemistry, manufacturing and controls review and in pre-approval inspections.¹ The white paper ties that approach to earlier patient access without compromising quality, safety or effectiveness standards.² FDA has not said how risk would be defined, which products would qualify or what data manufacturers would need to provide.

What regulatory flexibilities already exist for rare disease drugs?

A 2024 Government Accountability Office report, cited in the white paper, counted 18 rare disease programs at FDA, most launched since 2019.² In September 2025, the agency outlined its Rare Disease Evidence Principles process for products aimed at very small populations with significant unmet need and a known genetic defect as the major driver of disease.

Under that process, one adequate and well-controlled study, which may be single-arm, plus robust confirmatory evidence may generally establish substantial evidence of effectiveness.³ The white paper states that about half of recent novel approvals from the two product centers were for rare diseases, and describes the new initiative as an effort to systematize existing programs into one cross-center approach.²

Why does rare disease drug development remain a high unmet need?

Only about 5% of rare conditions have an FDA-approved treatment, according to the agency.¹ The white paper estimates that 30 million Americans live with a rare disease and says limited natural history data, missing validated biomarkers and disease heterogeneity complicate trial design.²

As a result, many patients receive therapies approved for other indications rather than ones shown to work in their own condition.² A 2019 analysis of 379 rare diseases put the annual U.S. economic burden at $997 billion, including $449 billion in direct medical costs.⁴ That figure is a modeled estimate and covers a subset of rare conditions.

What are the limitations and next steps?

The announcement sets goals rather than criteria and gives no date for a finished framework; the white paper says the agency will take the time required.²

Acting FDA Commissioner Kyle Diamantas, J.D., said: “The FDA will fight hard for patients by building a more consistent, predictable, and innovative approach to rare disease drug development while maintaining the rigorous standards Americans expect from the FDA.”¹

Whether that consistency materializes will depend on how review divisions apply any new guidance and on how fit-for-purpose evidence expectations are defined within the statutory standard. Both documents are agency statements, and no independent assessment of the initiative’s effect is available yet. Sponsors and other stakeholders can submit input at the Oct. 28 meeting and in the opportunities that follow.¹

Sources

U.S. Food and Drug Administration. FDA launches the Rare Disease Framework Initiative to develop a holistic, fit-for-purpose framework for rare disease drug development. News release. October 14, 2026. Accessed October 14, 2026. https://www.fda.gov/news-events/press-announcements/fda-launches-rare-disease-framework-initiative-develop-holistic-fit-purpose-framework-rare-disease
U.S. Food and Drug Administration. A new framework for rare disease review. White paper. October 2026. Accessed October 14, 2026. https://www.fda.gov/media/195694/download
FDA Rare Disease Innovation Hub. Rare Disease Evidence Principles: a proposed process to facilitate the approval of drugs to treat rare diseases. U.S. Food and Drug Administration. Accessed October 14, 2026. https://www.fda.gov/industry/fda-rare-disease-innovation-hub/cdercber-rare-disease-evidence-principles-rdep
Yang G, Cintina I, Pariser A, Oehrlein E, Sullivan J, Kennedy A. The national economic burden of rare disease in the United States in 2019. Orphanet J Rare Dis. 2022;17(1):163. doi:10.1186/s13023-022-02299-5